Gutiérrez Gutiérrez, GerardoGómez Ballesteros, RocíoAres, AdriánVillaverde, RamónReyes, VirginiaArmangué, ThaísDíaz Abós, PaolaRebollo, PabloCanal, NeusEt. al.2026-02-202026-02-202026Gutiérrez-Gutiérrez, G., Gómez-Ballesteros, R., Ares, A., Villaverde, R., Reyes, V., Armangué, T., Díaz-Abós, P., Rebollo, P., Canal, N., Querol, L., Maurino, J., & Cortés-Vicente, E. (2026). Neurologists’ decision-making in the management of generalised myasthenia gravis: Therapeutic inertia and treatment choices. Journal of Neuromuscular Diseases, 22143602261420993. https://doi.org/10.1177/221436022614209932214-35992214-3602https://hdl.handle.net/11268/16860The evolving landscape of generalised myasthenia gravis (gMG) treatment with new targeted immunotherapy options presents challenges for neurologists and potentially leads to therapeutic inertia (TI), the failure to initiate or intensify treatment when therapeutic goals are not met. This study aimed to assess neurologists’ therapeutic decision-making process in gMG and its influencing factors. A cross-sectional, web-based study was conducted, involving 149 neurologists.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Miastenia gravisToma de decisiones clínicasNeurólogosjournal article10.1177/22143602261420993open accessNeurologíaPersonal médicoMedicina preventivaGoal 3: Ensure healthy lives and promote well-being for all at all ages